Clinical experience with serotonin reuptake inhibiting antidepressants.
The development of a new class of antidepressants that have in common their ability to inhibit the reuptake of serotonin at neuronal synapses is reviewed. There is accumulating evidence that this class of medications constitutes an advance in the management of depression; these drugs appear to be effective antidepressants with a possibly lower and more acceptable incidence of adverse reactions than the tricyclic compounds. Further exploration of these potential advantages and of the usefulness of this group of compounds for other clinical syndromes is justified.
D015283:Citalopram; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy*; D005473:Fluoxetine / Q000627:therapeutic use; D016666:Fluvoxamine; D006801:Humans; D010091:Oximes / Q000627:therapeutic use; D011437:Propylamines / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D015031:Zimeldine / Q000627:therapeutic use
D010091:Oximes; D011437:Propylamines; D012702:Serotonin Antagonists; D005473:Fluoxetine; D015283:Citalopram; D015031:Zimeldine; D016666:Fluvoxamine